



# QUALITY OF LIFE AND PATIENT-REPORTED OUTCOMES WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB

4CPS-078

L01-  
ANTINEO  
PLASTIC  
AGENTS

Mañes Sevilla M, Vazquez Castillo MJ, Pousada Fonseca A, Segura Bedmar M.  
SERVICIO DE FARMACIA. HOSPITAL UNIVERSITARIO DE MÓSTOLES.

## BACKGROUND

Multiple myeloma (MM) is an incurable and chronic disease, so the quality of life (QoL) of patients with MM is an important criterion to consider. The patient-reported outcomes (PROs) are a fundamental tool to know the success of a treatment in clinical practice.

## AIM AND OBJECTIVES

Assessing QoL as a PROs in adult with MM treated with daratumumab.

## MATERIALS AND METHODS

**Retrospective observational** study which included patients with MM treated with daratumumab in a second level Hospital. (January-2019 to April-2023).

The electronic medical record were used to search patients and treatments variables.

QoL was analyzed using a **standardized** questionnaire (EORTC QLQ-C30 v3) and the **MM-specific** questionnaire (QLQ-MY20) to be answered by the **patients themselves**. The items to be answered were the presence of symptoms classifying as: "not at all", "a little", "quite" and "a lot".

The **general health** and the **QoL** were assessed with a score of 1 to 7, being 1 terrible and 7 excellent.

## RESULTS


Of the 39 patients (58.97% men, median age 70 years) treated with daratumumab in the study period, **11 completed the questionnaires.**

In 5 of them, it was completed on **2 occasions**: before starting/ during treatment

The average of treatments received at the time of completing the form was 23.25 months (SD:7.39)


➤ In active treatment, the responses were symptoms

Average points questionnaires



Legend for Symptoms:

- “not at all” (Green)
- “a little” (Pink)
- “quite a bit” (Yellow)
- “a lot” (Blue)



## CONCLUSIONS

In general, the presence of symptoms or problems related to the disease were mostly considered by the patients themselves as null. In addition, general health and QoL improving in the patients who were given the questionnaire at the beginning and during treatment with daratumumab.